On May 6, 2025, Guggenheim analyst Subbu Nambi reaffirmed his positive outlook on Twist Bioscience (TWST, Financial), maintaining a "Buy" rating on the stock. The price target remains steady at $50.00, consistent with the previous target.
The reiteration by Guggenheim reflects continued confidence in Twist Bioscience's (TWST, Financial) performance and potential in the market. The stock is listed on the NASDAQ exchange, but the focus remains solely on the ticker TWST in this report.
Investors following Twist Bioscience (TWST, Financial) will note that while the price target and ratings remain unchanged, this stability might suggest a consistent outlook from Guggenheim despite any market fluctuations.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for Twist Bioscience Corp (TWST, Financial) is $51.47 with a high estimate of $62.00 and a low estimate of $44.00. The average target implies an upside of 46.87% from the current price of $35.05. More detailed estimate data can be found on the Twist Bioscience Corp (TWST) Forecast page.
Based on the consensus recommendation from 13 brokerage firms, Twist Bioscience Corp's (TWST, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Twist Bioscience Corp (TWST, Financial) in one year is $59.61, suggesting a upside of 70.1% from the current price of $35.045. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Twist Bioscience Corp (TWST) Summary page.
